Starbucks stock price slips after hours as Wall Street lines up earnings and investor day (SBUX)
27 January 2026
1 min read

Starbucks stock price slips after hours as Wall Street lines up earnings and investor day (SBUX)

New York, Jan 26, 2026, 21:05 EST — The market has closed.

Starbucks Corp’s shares dipped roughly 1.3% in light after-hours trading Monday, last seen at $96.33, down from the regular session close of $97.61.

U.S. markets remain closed until Tuesday, but investors won’t have long to wait for Starbucks updates: the company’s fiscal first-quarter earnings call is set for Jan. 28, followed by an investor day on Jan. 29. 1

Why it matters now is straightforward: the company needs to show its turnaround is gaining momentum, and these events are where management must back that up with hard data. CEO Brian Niccol has claimed the “Back to Starbucks” plan is “taking hold,” highlighting a rebound in global comparable sales growth. 2

UBS analysts forecast revenue climbing about 2.5% year-over-year to $9.63 billion, despite a drop in earnings per share to $0.57 from $0.69. They also predict U.S. same-store sales — tracking outlets open at least a year — will rise 3% to 4%, beating the 1.9% consensus referenced in their report. 3

Mizuho analyst Nick Setyan bumped his price target on Starbucks to $95 from $86 but maintained a Neutral rating ahead of the earnings report. He noted “little risk” to Starbucks’ fiscal 2026 same-store sales growth forecasts, though he cautioned that consensus operating margin estimates seem overly optimistic; operating margin measures profit as a percentage of sales. 4

Jefferies remained cautious, sticking with an Underperform rating and a $75 price target. The firm cited several downside risks: margin pressure from labor reinvestment, the launch of an assistant store manager program, and rising coffee costs. It also highlighted Second Measure card-spending data that showed a sequential drop in first-quarter sales. 5

After the bell, a proxy filing revealed Starbucks plans its annual meeting for March 25. Shareholders will vote on directors, executive “say-on-pay” compensation, and several shareholder proposals. The agenda covers everything from voting-rule adjustments to board structure changes and reports on other policies, the filing noted. 6

Bernstein SocGen Group kept its Outperform rating and $100 price target intact, but warned gains might stall without a clear strategy from management to speed up margin recovery. The firm anticipates a sequential boost in same-store sales and a bounce back to positive comps after six straight quarters in the red. 7

The downside is straightforward. If the sales boost mainly comes from easier comparisons and fewer stores—not from real traffic growth—and costs remain stubborn, guidance could deteriorate fast, sending the stock tumbling.

Starbucks will address investors Wednesday morning, followed by a full investor day the next day. Traders see those targets as the key benchmark for the year ahead.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Uber stock slips as NYC forces 10% tip prompt on Uber Eats orders; focus turns to Feb. 4 earnings
Previous Story

Uber stock slips as NYC forces 10% tip prompt on Uber Eats orders; focus turns to Feb. 4 earnings

Citigroup stock edges higher as harassment lawsuit hits headlines ahead of Fed meeting
Next Story

Citigroup stock edges higher as harassment lawsuit hits headlines ahead of Fed meeting

Go toTop